Company Overview
Evolent Health, Inc. operates as a specialized provider within the Healthcare sector, specifically focusing on the Health Information Services industry, where it delivers critical administrative and specialty care management solutions. Through its subsidiary network, the firm executes its core mission by offering integrated value-based care platforms for health plan administration alongside targeted management services in oncology, cardiology, and musculoskeletal markets throughout the United States. The company currently commands a market capitalization of $253.42M and generates total annual revenue of $1.88B, supported by an operational workforce of 4,200 employees. These financial dimensions indicate a mid-sized enterprise with significant revenue generation capabilities that currently struggles to translate into profitability at a scale consistent with its operational footprint.
Financial Health
The company reports a trailing twelve-month revenue of $1.88B, yet it simultaneously records a net income of -$579,401,024 and an EBITDA of $88.22M, revealing a substantial gap between top-line generation and bottom-line profitability that highlights a strained cost structure. This divergence suggests that operating expenses and other costs are consuming the majority of revenue before interest and taxes, resulting in a net loss that far exceeds the negative operating earnings. Despite the significant net loss, the entity maintains a free cash flow of $98.41M, which provides a critical buffer for financial flexibility and operational continuity despite the reported accounting losses. The gross margin stands at 21.3%, indicating that the company retains a moderate portion of revenue after direct costs, while the operating margin of -2.1% and profit margin of -28.5% demonstrate severe inefficiencies in converting revenue into operating and net earnings. On the balance sheet, the company holds $151.86M in cash against $989.70M in total debt, a disparity reflected in a debt-to-equity ratio of 238.37, which characterizes the capital structure as highly leveraged. Liquidity is supported by a current ratio of 1.31, suggesting the company possesses sufficient short-term assets to cover its immediate liabilities, although the high leverage limits long-term strategic maneuvering. Furthermore, the return on equity is -66.5% and the return on assets is -0.1%, metrics that indicate management is currently unable to generate returns on the capital invested in the business.
Valuation Assessment
The valuation metrics present a complex picture, with a trailing P/E ratio listed as N/A due to the lack of positive earnings, while the forward P/E is calculated at 5.14, implying a market expectation of future earnings recovery that has not yet materialized in current financial statements. The price-to-book ratio is 0.61, indicating that the market values the company at less than its book value, which often signals that the market discounts the firm's assets or anticipates continued earnings challenges. Alternative valuation measures such as the price-to-sales ratio of 0.14 and an EV/EBITDA of 12.37 provide context for valuation relative to revenue and operating cash generation, suggesting the stock trades at a significant discount to its sales base. Regarding price momentum, the 52-week high is $12.06 and the 52-week low is $2.19, meaning the current share price sits significantly below the yearly peak and near the bottom of the established trading range. The beta value is 0.23, which indicates that the stock exhibits low volatility relative to the broader market, moving with much less intensity than the overall index.
Growth & Income
Revenue growth year-over-year is recorded at -27.5%, while earnings growth is N/A due to the absence of positive earnings, creating a scenario where the company is shrinking its top line without any earnings growth to offset the decline. The company does not distribute dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning the entity reinvests all available resources into operations rather than returning capital to shareholders. This lack of a dividend program is consistent with a firm in a restructuring phase or facing profitability hurdles, where cash retention is prioritized over shareholder payouts. The overall growth and income profile reflects a mature but distressed asset with declining revenue, no current income generation for shareholders, and a capital structure heavily weighted toward debt obligations.